Bio Green Med Solution, INC. (BGMS) — SEC Filings
Latest SEC filings for Bio Green Med Solution, INC.. Recent 8-K filing on Apr 13, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.
View Bio Green Med Solution, INC. on SEC EDGAR
Overview
Bio Green Med Solution, INC. (BGMS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: Bio Green Med Solution, Inc. (BGMS) underwent a significant strategic pivot in 2025, transforming from a clinical research company to a fire safety equipment and solutions provider. This transformation began with equity transactions in January 2025, where David E. Lazar purchased $3.1 million in Ser
Sentiment Summary
Across 2 filings, the sentiment breakdown is: 1 neutral, 1 mixed. The dominant filing sentiment for Bio Green Med Solution, INC. is neutral.
Filing Type Overview
Bio Green Med Solution, INC. (BGMS) has filed 1 8-K, 1 10-K with the SEC between Mar 2026 to Apr 2026.
Recent Filings (2)
- 8-K Filing — 8-K · Apr 13, 2026
-
Bio Green Med Solution Pivots to Fire Safety After Biotech Exit
— 10-K · Mar 30, 2026 Risk: medium
Bio Green Med Solution, Inc. (BGMS) underwent a significant strategic pivot in 2025, transforming from a clinical research company to a fire safety equipment an
Risk Profile
Risk Assessment: Of BGMS's 1 recent filings, 0 were flagged as high-risk, 1 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- David E. Lazar
- Datuk Dr. Doris Wong Sing Ee
Industry Context
Bio Green Med Solution, Inc. has pivoted to the fire safety equipment and solutions sector, primarily operating in Malaysia. This industry is characterized by a competitive landscape where companies like BGMS must compete with established players who may have greater financial resources. Key product areas include fire extinguishers, fire-resistant doors, and personal protective equipment, driven by demand for safety and compliance with building codes.
Top Tags
Corporate Restructuring (1) · Strategic Pivot (1) · Fire Safety Equipment (1) · Malaysia Market (1) · Reverse Stock Split (1) · Asset Sale (1) · Acquisition (1) · Going Concern (1)
Key Numbers
- Gross proceeds from preferred stock sale: $3.1M — Used to settle liabilities and for general corporate purposes in January 2025.
- Increase in stockholders' equity: $4.9M — Resulted from the deconsolidation of Cyclacel Limited on January 31, 2025.
- Sale price of Plogo assets: $300,000 — Received from Tethra Biosciences Inc. for patent rights related to plogosertib.
- Potential Milestone payment: $170,000 — Additional payment for Plogo assets from Tethra Biosciences Inc.
- Common shares issued for acquisition: 699,158 — Representing 19.99% of BGMS common shares issued to FITTERS Diversified Berhad.
- Market value of non-affiliate common stock: $3,024,225 — As of June 30, 2025, based on a closing price of $4.9543.
- Common stock shares outstanding: 5,519,456 — As of March 24, 2026.
- Reverse stock split ratio: 1-for-16 — Effected on May 12, 2025, for common stock.
- Further reverse stock split ratio: 1-for-15 — Effected on July 7, 2025, for common stock.
- Ownership stake: 70% — Datuk Dr. Doris Wong Sing Ee's ownership of fully diluted shares after preferred stock conversion.
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Bio Green Med Solution, INC. (BGMS)?
Bio Green Med Solution, INC. has 2 recent SEC filings from Mar 2026 to Apr 2026, including 1 8-K, 1 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BGMS filings?
Across 2 filings, the sentiment breakdown is: 1 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Bio Green Med Solution, INC. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bio Green Med Solution, INC. (BGMS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bio Green Med Solution, INC.?
Key financial highlights from Bio Green Med Solution, INC.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BGMS?
The investment thesis for BGMS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bio Green Med Solution, INC.?
Key executives identified across Bio Green Med Solution, INC.'s filings include David E. Lazar, Datuk Dr. Doris Wong Sing Ee.
What are the main risk factors for Bio Green Med Solution, INC. stock?
Of BGMS's 1 assessed filings, 0 were flagged high-risk, 1 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Bio Green Med Solution, INC.?
Forward guidance and predictions for Bio Green Med Solution, INC. are extracted from SEC filings as they are enriched.